Citations (84)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Gines Escolar, Maribel Diaz-Ricart, Eduardo Arellano-Rodrigo & Ana M Galán. (2014) The pharmacokinetics of edoxaban for the prevention and treatment of venous thromboembolism. Expert Opinion on Drug Metabolism & Toxicology 10:3, pages 445-458.
Read now
Read now
Stavros Apostolakis, Gregory YH Lip & Eduard Shantsila. (2013) Pharmacokinetic considerations for antithrombotic therapies in stroke. Expert Opinion on Drug Metabolism & Toxicology 9:10, pages 1335-1347.
Read now
Read now
Gualtiero Palareti, Walter Ageno, Annamaria Ferrari, Alessandro Filippi, Davide Imberti, Vittorio Pengo, Andrea Rubboli & Danilo Toni. (2013) Clinical management of rivaroxaban-treated patients. Expert Opinion on Pharmacotherapy 14:5, pages 655-667.
Read now
Read now
Peter P. Toth. (2012) Practical Management of Anticoagulants in Family Medicine after Orthopedic Surgery. Postgraduate Medicine 124:4, pages 206-214.
Read now
Read now
Lakshmi Gopalakrishnan, Varun Kumar, Payal Kohli, Priyamvada Singh, Ujjwal Rastogi & C. Michael Gibson. (2012) Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes. Expert Opinion on Drug Metabolism & Toxicology 8:7, pages 889-900.
Read now
Read now
Erica Romualdi, Marco P Donadini & Walter Ageno. (2011) Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-Extension study). Expert Review of Cardiovascular Therapy 9:7, pages 841-844.
Read now
Read now
Erica Romualdi, Francesco Dentali, Alessandro Squizzato & Walter Ageno. (2010) Thromboprophylaxis for hip and knee surgery: critical appraisal of rivaroxaban. Open Access Surgery 3, pages 27-33.
Read now
Read now
Nicholas Fassiadis. (2009) Rivaroxaban, the first oral, direct factor Xa inhibitor. Expert Opinion on Pharmacotherapy 10:18, pages 2945-2946.
Read now
Read now
Lars C Borris. (2009) Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty. Expert Opinion on Pharmacotherapy 10:6, pages 1083-1088.
Read now
Read now
Lars Carl Borris. (2008) New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. Vascular Health and Risk Management 4:4, pages 855-862.
Read now
Read now
Jonathan P Piccini, Manesh R Patel, Kenneth W Mahaffey, Keith AA Fox & Robert M Califf. (2008) Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opinion on Investigational Drugs 17:6, pages 925-937.
Read now
Read now
Articles from other publishers (73)
Pascal Kintz, Charlotte Allain, Laetitia Oertel, Emilie Feisthauer, Alice Ameline & Jean-Sébastien Raul. (2023) Complete investigations (autopsy, toxicology, and histology) in a death due to apixaban overdose. International Journal of Legal Medicine.
Crossref
Crossref
Xinyi Wang, Tongxin Wang, Xuanye Chen, Wende Tian, Dan Ma, Jie Zhang, Qiuyi Li, Zhuo Chen, Jianqing Ju, Hao Xu & Keji Chen. (2023) Efficacy and Safety of Oral Anticoagulants in Older Adult Patients With Atrial Fibrillation: Pairwise and Network Meta-Analyses. Journal of the American Medical Directors Association 24:8, pages 1233-1239.e26.
Crossref
Crossref
Prabhu Kumar K.M.Vasantha Kumar B.C.Sharath Kumar M.N.Raghavendra Kumar P.Devaraju S.Butcher R.J.Revanasiddappa H.D.. (2021) Synthesis, structural characterization, CT-DNA interaction study and antithrombotic activity of new ortho-vanillin-based chiral (Se,N,O) donor ligands and their Pd complexes. Inorganica Chimica Acta 528, pages 120609.
Crossref
Crossref
Junguo Zhang, Xiaojie Wang, Xintong Liu, Torben B. Larsen, Daniel M. Witt, Zebing Ye, Lehana Thabane, Guowei Li & Gregory Y. H. Lip. (2021) Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis. European Journal of Epidemiology 36:8, pages 793-812.
Crossref
Crossref
Masahiro Ieko, Kazumasa Ohmura, Sumiyoshi Naito, Mika Yoshida, Ichiro Sakuma, Kozue Ikeda, Shouko Ono, Takeshi Suzuki & Nobuhiko Takahashi. (2020) Novel assay based on diluted prothrombin time reflects anticoagulant effects of direct oral factor Xa inhibitors: Results of multicenter study in Japan. Thrombosis Research 195, pages 158-164.
Crossref
Crossref
Huda H. Satti, Eman F. Khaleel, Rehab M. Badi, Amany O. Elrefaie & Dalia G. Mostafa. (2020) Subacute administration of Astaxanthin inhibits vitamin K‐dependent clotting factors in rats. Journal of Food Biochemistry 44:10.
Crossref
Crossref
Abdullah S. Shatoor, Ali Shati, Sulaiman M. Al Humayed, Abdulaziz K. Shatoor, Naif M. Alhawiti & Sultan A. Alqahtani. (2019)
The hypocoagulant effect of
Crataegus aronia
in rats entails vitamin K‐dependent and vitamin K‐independent effects
. Journal of Food Biochemistry 44:1.
Crossref
Crossref
Thomas E. Grissom. (2018) Management of the Trauma Patient on Direct Oral
Anticoagulants. Current Anesthesiology Reports 8:1, pages 107-118.
Crossref
Crossref
Jonathan Bar, Alexa David, Tarek Khader, Mary Mulcare & Christopher Tedeschi. (2017) Assessing Coagulation by Rotational Thromboelastometry (ROTEM) in Rivaroxaban-Anticoagulated Blood Using Hemostatic Agents. Prehospital and Disaster Medicine 32:5, pages 580-587.
Crossref
Crossref
AF Roffel, SP van Marle, S Choi, HJ Lee, SR Dueker & RG Tiessen. (2017) Metabolism and excretion of GCC-4401C, a factor Xa inhibitor, in humans. International Journal of Pharmacokinetics 2:2, pages 93-104.
Crossref
Crossref
Soo Lee, Wonhwa Lee, Jong-Sup Bae & Eunsook Ma. (2016) Synthesis and in Vitro and in Vivo Anticoagulant and Antiplatelet Activities of Amidino- and Non-Amidinobenzamides. Molecules 21:5, pages 676.
Crossref
Crossref
I. N. Pasechnik. (2016) The use of new oral anticoagulants in surgery. Part 1. Khirurgiya. Zhurnal im. N.I. Pirogova:2, pages 72.
Crossref
Crossref
Rick van Gorp & Leon Schurgers. (2015) New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs). Nutrients 7:11, pages 9538-9557.
Crossref
Crossref
Jiabin Yang, Guoqiang Su, Yu Ren & Yang Chen. (2015) Synthesis of 3,4-diaminobenzoyl derivatives as factor Xa inhibitors. European Journal of Medicinal Chemistry 101, pages 41-51.
Crossref
Crossref
N. V. Zagorodniy & K. M. Bukhtin. (2015) Use of Rivaroxaban for Prevention of Thromboembolism after Major Joints Arthroplasty under Conditions of Real Clinical Practice in Russia (on the data of prospective multicenter non-interventional study SOPRANO). Vestnik travmatologii i ortopedii imeni N.N. Priorova:1, pages 84-90.
Crossref
Crossref
N. V Zagorodniy & K. M Bukhtin. (2015) Use of Rivaroxaban for Prevention of Thromboembolism after Major Joints Arthroplasty under Conditions of Real Clinical Practice in Russia (on the data of prospective multicenter non-interventional study SOPRANO). N.N. Priorov Journal of Traumatology and Orthopedics 22:1, pages 84-90.
Crossref
Crossref
H. Forst, T. Fuchs-Buder, Axel R. Heller & M. WeigandA. Giebl & K. Gürtler. 2015. Weiterbildung Anästhesiologie. Weiterbildung Anästhesiologie
107
122
.
Lizheng Mao, Chengyan Li, Tao Li & Kunxiong Yuan. (2013) Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation. Vascular 22:4, pages 252-258.
Crossref
Crossref
A. Giebl & K. Gürtler. (2014) Neue orale Antikoagulanzien in der perioperativen MedizinNew oral anticoagulants in perioperative medicine. Der Anaesthesist 63:4, pages 347-364.
Crossref
Crossref
Eduard Shantsila & Gregory Y.H. Lip. (2014) Use of Novel Oral Anticoagulants in Patients With Heart Failure. Current Treatment Options in Cardiovascular Medicine 16:2.
Crossref
Crossref
Anahita Dabo-Trubelja & Eric R. Kelhoffer. 2014. Radical Prostatectomy. Radical Prostatectomy
31
48
.
Emine Gazi, Ahmet Temiz, Ahmet Barutcu & Yucel Colkesen. (2013) Novel Therapeutics for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. Drug Development Research 74:7, pages 485-491.
Crossref
Crossref
Troy C. Sarich, Gary Peters, Scott D. Berkowitz, Frank Misselwitz, Christopher C. Nessel, Paul Burton, Nancy Cook-Bruns, Anthonie W.A. Lensing, Lloyd Haskell, Elisabeth Perzborn, Dagmar Kubitza, Kenneth T. Moore, Sanjay Jalota, Juergen Weber, Guohua Pan, Xiang Sun, Torsten Westermeier, Andrea Nadel, Leonard Oppenheimer & Peter M. DiBattiste. (2013) Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Annals of the New York Academy of Sciences 1291:1, pages 42-55.
Crossref
Crossref
Uroš Trstenjak, Janez Ilaš & Danijel Kikelj. (2013) Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores. European Journal of Medicinal Chemistry 64, pages 302-313.
Crossref
Crossref
Xavier Delavenne, Patrick Mismetti & Thierry Basset. (2013) Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 78-79, pages 150-153.
Crossref
Crossref
José Mateo. (2013) Nuevos anticoagulantes orales y su papel en la práctica clínica. Revista Española de Cardiología Suplementos 13, pages 33-41.
Crossref
Crossref
M. Casutt, C. Konrad & G. Schuepfer. (2012) Effect of rivaroxaban on blood coagulation using the viscoelastic coagulation test ROTEM™Effekt von Rivaroxaban auf die Blutgerinnung, gemessen mit dem viskoelastischen Gerinnungstest ROTEM™. Der Anaesthesist 61:11, pages 948-953.
Crossref
Crossref
T. FUNATSU, Y. IWATSUKI & S. KAKU. (2012) Darexaban has high sensitivity in the prothrombin time clotting test. Journal of Thrombosis and Haemostasis 10:4, pages 703-705.
Crossref
Crossref
Yaroslav Winter, Richard Dodel, Alexei Korchounov, Martin Grond, Wolfgang H. Oertel & Tobias Back. (2012) Clinical and pharmacological properties of new oral anticoagulants for the prevention of cerebral thromboembolism: Factor Xa and thrombin inhibitors. World Journal of Neuroscience 02:01, pages 7-14.
Crossref
Crossref
Job Harenberg, Svetlana Marx, Martin Krejczy & Martin Wehling. (2011) New anticoagulants – promising and failed developments. British Journal of Pharmacology 165:2, pages 363-372.
Crossref
Crossref
Abhishek Maan, Ram Padmanabhan, Amir Y. Shaikh, Moussa Mansour, Jeremy N. Ruskin & E. Kevin Heist. (2012) Newer Anticoagulants in Cardiovascular Disease. Cardiology in Review 20:5, pages 209-221.
Crossref
Crossref
Job Harenberg & Martin Wehling. (2011) Future of Anticoagulant Therapy. Cardiovascular Therapeutics 29:5, pages 291-300.
Crossref
Crossref
Angelo C. Molinari, Paola Saracco, Valerio Cecinati, Maurizio Miano, Emilia Parodi, Massimo Grassi, Laura Banov, Domenico De Mattia & Paola Giordano. (2011) Venous thrombosis in children. Blood Coagulation & Fibrinolysis 22:5, pages 351-361.
Crossref
Crossref
Alexander Straub, Susanne Roehrig & Alexander Hillisch. (2011) Oral, Direct Thrombin and Factor Xa Inhibitors: The Replacement for Warfarin, Leeches, and Pig Intestines?. Angewandte Chemie International Edition 50:20, pages 4574-4590.
Crossref
Crossref
Alexander Straub, Susanne Roehrig & Alexander Hillisch. (2011) Orale, direkte Thrombin‐ und Faktor‐Xa‐Hemmer: Kommt die Ablösung für Warfarin, Blutegel und Schweinedärme?. Angewandte Chemie 123:20, pages 4670-4686.
Crossref
Crossref
Rolf Burghaus, Katrin Coboeken, Thomas Gaub, Lars Kuepfer, Anke Sensse, Hans-Ulrich Siegmund, Wolfgang Weiss, Wolfgang Mueck & Joerg Lippert. (2011) Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer
Model for Blood Coagulation. PLoS ONE 6:4, pages e17626.
Crossref
Crossref
Thomas Mavrakanas & Henri Bounameaux. (2011) The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism. Pharmacology & Therapeutics 130:1, pages 46-58.
Crossref
Crossref
Yu‐Kai Lee & Mark R. Player. (2011) Developments in factor Xa inhibitors for the treatment of thromboembolic disorders. Medicinal Research Reviews 31:2, pages 202-283.
Crossref
Crossref
Satoshi Ogawa, Yukihiro Koretsune, Masahiro Yasaka, Yoshifusa Aizawa, Hirotsugu Atarashi, Hiroshi Inoue, Shiro Kamakura, Koichiro Kumagai, Hideo Mitamura, Ken Okumura, Kaoru Sugi & Takeshi Yamashita. (2011) Antithrombotic Therapy in Atrial Fibrillation. Circulation Journal 75:7, pages 1539-1547.
Crossref
Crossref
Alessandro Squizzato, Erica Romualdi, Francesco Dentali & Walter Ageno. (2010) The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery?. Current Opinion in Anaesthesiology 23:6, pages 722-725.
Crossref
Crossref
S. Siebenlist, S. Haas, F. Elser & U. Stöckle. (2010) Neue orale Antikoagulanzien aus unfallchirurgischer SichtNew oral anticoagulants from the perspective of trauma surgery. Der Unfallchirurg 113:11, pages 886-892.
Crossref
Crossref
Donald J. AbrahamBrian L. Henry & Umesh R. Desai. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
365
408
.
T A Leil, Y Feng, L Zhang, A Paccaly, P Mohan & M Pfister. (2010) Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose. Clinical Pharmacology & Therapeutics 88:3, pages 375-382.
Crossref
Crossref
S. Schulman. (2010) New aspects on treatment modalities for thromboembolic episodes. Journal of Internal Medicine 268:2, pages 109-119.
Crossref
Crossref
Erica Romualdi & Walter Ageno. (2010) Oral Xa Inhibitors. Hematology/Oncology Clinics of North America 24:4, pages 727-737.
Crossref
Crossref
Takuya Fujimoto, Yasuhiro Imaeda, Noriko Konishi, Katsuhiko Hiroe, Masaki Kawamura, Garret P. Textor, Kathleen Aertgeerts & Keiji Kubo. (2010)
Discovery of a Tetrahydropyrimidin-2(1
H
)-one Derivative (TAK-442) as a Potent, Selective, and Orally Active Factor Xa Inhibitor
. Journal of Medicinal Chemistry 53:9, pages 3517-3531.
Crossref
Crossref
Milan Remko. (2009) Molecular structure, lipophilicity, solubility, absorption, and polar surface area of novel anticoagulant agents. Journal of Molecular Structure: THEOCHEM 916:1-3, pages 76-85.
Crossref
Crossref
Takuya Fujimoto, Mamoru Tobisu, Noriko Konishi, Masaki Kawamura, Norio Tada, Terufumi Takagi & Keiji Kubo. (2009) Synthesis and biological evaluation of the metabolites of 2-(1-{3-[(6-chloronaphthalen-2-yl)sulfonyl]propanoyl}piperidin-4-yl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one. Bioorganic & Medicinal Chemistry 17:23, pages 7993-8002.
Crossref
Crossref
Luciana Armaganijan, John Eikelboom, Jeff S. Healey & Carlos A. Morillo. (2010) New pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010. Advances in Therapy 26:12, pages 1058-1071.
Crossref
Crossref
Juan V Llau & Raquel Ferrandis. (2009) New anticoagulants and regional anesthesia. Current Opinion in Anaesthesiology 22:5, pages 661-666.
Crossref
Crossref
Donglu Zhang, Kan He, Nirmala Raghavan, Lifei Wang, James Mitroka, Brad D. Maxwell, Robert M. Knabb, Charles Frost, Alan Schuster, Feng Hao, Zheming Gu, W. Griffith Humphreys & Scott J. Grossman. (2009)
Comparative Metabolism of
14
C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans
. Drug Metabolism and Disposition 37:8, pages 1738-1748.
Crossref
Crossref
Rakesh Gopinathannair, Renee M. Sullivan & Brian Olshansky. (2009) Update on medical management of atrial fibrillation in the modern era. Heart Rhythm 6:8, pages S17-S22.
Crossref
Crossref
Xia Zhao, Peihong Sun, Ying Zhou, Yuwang Liu, Huilin Zhang, Wolfgang Mueck, Dagmar Kubitza, Richard J. Bauer, Hong Zhang & Yimin Cui. (2009) Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. British Journal of Clinical Pharmacology 68:1, pages 77-88.
Crossref
Crossref
Sam Schulman. 2009. New Therapeutic Agents in Thrombosis and Thrombolysis. New Therapeutic Agents in Thrombosis and Thrombolysis
155
170
.
D. Lang, C. Freudenberger & C. Weinz. (2009) In Vitro Metabolism of Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Liver Microsomes and Hepatocytes of Rats, Dogs, and Humans. Drug Metabolism and Disposition 37:5, pages 1046-1055.
Crossref
Crossref
Sylvia Haas. (2009) Rivaroxaban - an oral, direct Factor Xa inhibitor - lessons from a broad clinical study programme. European Journal of Haematology 82:5, pages 339-349.
Crossref
Crossref
Matthias Orth. (2009) Factor II- and factor Xa-inhibitors for prevention and treatment of thromboses / Faktor II- und Faktor Xa-Inhibitoren in der Prävention und Therapie von Thrombosen. LaboratoriumsMedizin 33:2, pages 121-127.
Crossref
Crossref
Paris J. Abrams & Christopher R. Emerson. (2012) Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29:2, pages 167-181.
Crossref
Crossref
Nirmala Raghavan, Charles E. Frost, Zhigang Yu, Kan He, Haiying Zhang, W. Griffith Humphreys, Donald Pinto, Shiangyuan Chen, Samuel Bonacorsi, Pancras C. Wong & Donglu Zhang. (2009) Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans. Drug Metabolism and Disposition 37:1, pages 74-81.
Crossref
Crossref
Renato D. Lopes, Jonathan P. Piccini, Elaine M. Hylek, Christopher B. Granger & John H. Alexander. (2008) Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. Journal of Thrombosis and Thrombolysis 26:3, pages 167-174.
Crossref
Crossref
P. SAVI, J.P. HERAULT, P. DUCHAUSSOY, L. MILLET, P. SCHAEFFER, M. PETITOU, F. BONO & J.M. HERBERT. (2008) Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. Journal of Thrombosis and Haemostasis 6:10, pages 1697-1706.
Crossref
Crossref
Janez Ilaš, Žiga Jakopin, Tina Borštnar, Mojca Stegnar & Danijel Kikelj. (2008)
3,4-Dihydro-2
H
-1,4-benzoxazine Derivatives Combining Thrombin Inhibitory and Glycoprotein IIb/IIIa Receptor Antagonistic Activity as a Novel Class of Antithrombotic Compounds with Dual Function
. Journal of Medicinal Chemistry 51:18, pages 5617-5629.
Crossref
Crossref
Yasuhiro Imaeda, Takanobu Kuroita, Hiroki Sakamoto, Tetsuji Kawamoto, Mamoru Tobisu, Noriko Konishi, Katsuhiko Hiroe, Masaki Kawamura, Toshimasa Tanaka & Keiji Kubo. (2008)
Discovery of Imidazo[1,5-
c
]imidazol-3-ones: Weakly Basic, Orally Active Factor Xa Inhibitors
. Journal of Medicinal Chemistry 51:12, pages 3422-3436.
Crossref
Crossref
Job Harenberg. (2008) Indirect and direct anticoagulants predominantly inhibiting factor Xa. Therapy 5:2, pages 177-192.
Crossref
Crossref
Yasuhiro Imaeda, Toshio Miyawaki, Hiroki Sakamoto, Fumio Itoh, Noriko Konishi, Katsuhiko Hiroe, Masaki Kawamura, Toshimasa Tanaka & Keiji Kubo. (2008) Discovery of sulfonylalkylamides: A new class of orally active factor Xa inhibitors. Bioorganic & Medicinal Chemistry 16:5, pages 2243-2260.
Crossref
Crossref
Sylvia Haas. (2007) New oral Xa and IIa inhibitors: updates on clinical trial results. Journal of Thrombosis and Thrombolysis 25:1, pages 52-60.
Crossref
Crossref
Valentine J. Klimkowski, Brian M. Watson, Michael R. Wiley, John Liebeschuetz, Jeffry B. Franciskovich, Jothirajah Marimuthu, Jolie A. Bastian, Daniel J. Sall, Jeffrey K. Smallwood, Nikolay Y. Chirgadze, Gerald F. Smith, Ronald S. Foster, Trelia Craft, Philip Sipes, Marcia Chastain & Scott M. Sheehan. (2007) d-Phenylglycinol-derived non-covalent factor Xa inhibitors: Effect of non-peptidic S4 linkage elements on affinity and anticoagulant activity. Bioorganic & Medicinal Chemistry Letters 17:21, pages 5801-5805.
Crossref
Crossref
Qing Ma. (2007) Development of oral anticoagulants. British Journal of Clinical Pharmacology 64:3, pages 263-265.
Crossref
Crossref
Anne Stürzebecher, Daniel Dönnecke, Andrea Schweinitz, Oliver Schuster, Peter Steinmetzer, Uta Stürzebecher, Joscha Kotthaus, Bernd Clement, Jörg Stürzebecher & Torsten Steinmetzer. (2007) Highly Potent and Selective Substrate Analogue Factor Xa Inhibitors ContainingD-Homophenylalanine Analogues as P3 Residue: Part 2. ChemMedChem 2:7, pages 1043-1053.
Crossref
Crossref
J. ANSELL. (2007) Factor Xa or thrombin: is factor Xa a better target?. Journal of Thrombosis and Haemostasis 5, pages 60-64.
Crossref
Crossref
A. G.G. Turpie. (2007) Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases. Arteriosclerosis, Thrombosis, and Vascular Biology 27:6, pages 1238-1247.
Crossref
Crossref
Daniel Dönnecke, Andrea Schweinitz, Anne Stürzebecher, Peter Steinmetzer, Maj Schuster, Uta Stürzebecher, Silke Nicklisch, Jörg Stürzebecher & Torsten Steinmetzer. (2007) From selective substrate analogue factor Xa inhibitors to dual inhibitors of thrombin and factor Xa. Part 3. Bioorganic & Medicinal Chemistry Letters 17:12, pages 3322-3329.
Crossref
Crossref
Chuen Chan, Alan D. Borthwick, David Brown, Cynthia L. Burns-Kurtis, Matthew Campbell, Laiq Chaudry, Chun-wa Chung, Máire A. Convery, J. Nicole Hamblin, Lisa Johnstone, Henry A. Kelly, Savvas Kleanthous, Angela Patikis, Champa Patel, Anthony J. Pateman, Stefan Senger, Gita P. Shah, John R. Toomey, Nigel S. Watson, Helen E. Weston, Caroline Whitworth, Robert J. Young & Ping Zhou. (2007)
Factor Xa Inhibitors: S1 Binding Interactions of a Series of
N
-{(
3S
)-1-[(
1S
)-1-Methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamides
. Journal of Medicinal Chemistry 50:7, pages 1546-1557.
Crossref
Crossref